Treatment of Functional Neurological Disorders Authors: Jung E Park Published: 2026 ABSTRACT Functional neurological disorder (FND) is a common condition characterized by involuntary neurological symptoms. The most common subtypes include functional/dissociative seizures and functional movement disorders, though other presentations such as persistent postural-perceptual dizziness and functional cognitive disorder are increasingly recognized. Patients may present with multiple types of functional neurological symptoms, and comorbid pain, fatigue, and sleep disturbance are common and may substantially affect quality of life. Despite its high prevalence, FND has historically been neglected, and the prognosis remains poor in a substantial proportion of patients. This article provides an overview of current treatment options for FND, including physical therapy, cognitive behavioral therapy, multidisciplinary approaches, and neuromodulation. Ongoing challenges including heterogeneous outcome measures, limited long-term follow-up data, the absence of validated biomarkers, and the need for expanded access to specialist care are also discussed. INTRODUCTION Functional neurological disorder (FND) is a common and complex condition characterized by involuntary neurological symptoms. This disorder presents across a range of clinical settings depending on symptom acuity and severity, most commonly in outpatient clinics and emergency departments (EDs).1 FND has been reported to be among the most common reasons for outpatient visits and is associated with significant use of healthcare resources.234 The most common subtypes include functional/dissociative seizures (previously referred to as psychogenic nonepileptic seizures and referred to hereafter as functional seizures) and functional movement disorders (FMDs).56 FMDs can present with a wide range of phenomenology including tremor, myoclonus, dystonia, parkinsonism, tics and/or paresis.5 FND can present in a mixed fashion and can also occur in the presence of other neurological disorders such as Parkinson’s disease or epileptic seizures. Functional speech, dizziness, cognitive or sensory symptoms can also present independently or concurrently. Therefore, it is important to perform a thorough assessment of all symptoms and carefully determine which symptoms may be part of FND or other neurological and medical conditions. Because fatigue, pain, and sleep disturbances can also occur and may substantially affect patients’ quality of life, screening for these symptoms should be considered. Historically, various terms have been used to describe FND, including now-unacceptable terms such as “hysteria” and “pseudoseizures.” Conversion disorder is also a commonly used term; however, in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), it is included in parentheses next to Functional Neurological Symptom Disorder.7 Furthermore, the term functional movement disorder has been proposed in place of psychogenic movement disorder, due to the potentially negative connotations associated with the latter.8 Recently, there has also been a proposal to replace the widely used term “psychogenic nonepileptic seizures” (PNES) with the term “functional/dissociative seizures” (FDS).9 These terminological shifts reflect ongoing efforts to reduce stigma and align clinical language with current pathophysiological understanding. Despite the high prevalence of FND and its variable impact on patients’ quality of life depending on symptom type and severity, studies have shown that this condition has been largely neglected. Recent literature has increasingly highlighted stigma, underscoring the need for clinician education, public awareness, and structural healthcare changes to improve patient care.10 A study utilizing questionnaires found that even among neurologists, knowledge about scientific advances in FND is sparse, suggesting a further need for professional education on the understanding of this disorder.11 This review provides an overview of current treatment options for FND and discusses ongoing challenges and limitations in the evidence base and in clinical practice. Literature for this review was identified through PubMed searches and manual screening of key guidelines and systematic reviews; priority was given to randomized controlled trials (RCTs), systematic reviews, meta-analyses, and clinical practice guidelines. While a focused review of FMD diagnosis, pathophysiology, and management was previously published by the author, the present review differs in scope and purpose by integrating treatment evidence across major FND subtypes, with particular attention to functional seizures, persistent postural-perceptual dizziness (PPPD), and functional cognitive disorder (FCD). It also situates the 2026 American Academy of Neurology (AAN) functional seizures guideline and the 2025 International League Against Epilepsy terminology proposal within a cross-subtype, treatment-centered synthesis, supported by a tiered treatment algorithm (Fig. 1) and evidence summary table (Table 1). To minimize overlap, established diagnostic signs and rehabilitation principles for FMD are summarized only briefly. The neuromodulation section, however, provides a focused appraisal of randomized FMD trials that were not examined in detail in the previous review.12 CLINICAL APPROACH AND PHENOMENOLOGY Successful treatment of FND begins with clear communication of the diagnosis and the patient’s willingness to accept it. Over the past decade, the importance of establishing FND using positive clinical features—rather than relying on a diagnosis of exclusion—has been increasingly emphasized.13 Positive signs such as Hoover’s sign, the hip abductor sign, and the “whack-a-mole” sign provide objective, observable evidence that supports a rule-in diagnosis.614 In contrast, pursuing diagnosis primarily through exclusion can lead to unnecessary uncertainty and may foster patient concerns that an underlying condition has been overlooked. The importance of actively involving patients has been emphasized, including demonstrating positive physical signs to facilitate understanding and acceptance of the diagnosis.15 Framing FND as a “software rather than hardware problem” has also been shown to aid patient understanding by emphasizing the functional and reversible nature of the disorder.13 Acceptance of the diagnosis itself has been associated with greater subsequent engagement with and response to physical therapy and psychological treatment across FND subtypes, suggesting that the diagnostic encounter functions as an early step in treatment. FND can often be recognized clinically, although this is not always possible. For example, functional seizures may differ from epileptic seizures in several ways: episodes may be prolonged, and typical motor features include irregular or discontinuous movements, asynchronous limb activity, side-to-side head shaking, and pelvic thrusting.1617 FMD may manifest with diverse phenomenology, including tremor, dystonia, jerks/myoclonus, facial symptoms/spasms, mixed symptoms and parkinsonism.18 Characteristic features of FMD include variability, distractibility, and entrainability.19 Making note of these characteristics on examination and sharing them with the patient can be useful in the delivery of diagnosis.13 Other types of FND include FCD and chronic dizziness, which have been recognized as part of the FND spectrum relatively more recently.520 PPPD is characterized by chronic dizziness, unsteadiness and non-spinning vertigo exacerbated by the patient’s own movements and exposure to visually complex or motion-rich environments.21 It has been reported to be the second most common cause of dizziness in specialty dizziness clinics.21 Although PPPD is a relatively recent diagnostic label, the condition it describes has been described in the medical literature under various earlier terms since the 19th century. Previously used terms include space-motion discomfort, visual vertigo, and chronic subjective dizziness. The diagnostic criteria for PPPD are summarized in Table 2, adapted from the Bárány Society consensus criteria.21 FCD refers to complaints of persistent problematic cognitive difficulties, when accompanied by positive features termed “internal inconsistency” which are not better explained by another disorder (such as a neurodegenerative disease process).20 Internal inconsistency refers to the ability to perform a task well at certain times, but with significantly impaired ability at other times, particularly when the task is the focus of attention. FCD is thought to be underdiagnosed, as many patients meet descriptive criteria for mild cognitive impairment or subjective cognitive decline. FCD may itself represent a prodromal syndrome in some cases and its relationship to neurodegenerative disease such as dementia warrants further investigation.22 Patients with FCD have been found not to consistently fail tests of performance validity or effort, but may display impaired selective attention.23 The proposed diagnostic criteria for FCD, adapted from Ball et al.,20 are presented in Table 3. APPROACH TO PEDIATRIC, GERIATRIC, AND EMERGENCY PRESENTATIONS While most of the interest in FND has been focused on the adult population, FND also occurs in children and the elderly. Studies reporting on the prevalence of FMD in the pediatric outpatient setting range from 5.7% to 15%.182425 The most common types of FMD have been reported to be tremor and dystonia.2426 Recent papers have also commented on the rise of sudden-onset FMD in both children and adults during the COVID-19 pandemic.27 Pediatric patients with FMD frequently present with additional somatic symptoms such as headache, fatigue, abdominal discomfort, and numbness.24 Challenges in the assessment and management of childhood FMDs include the absence of developmentally appropriate diagnostic interviews; the need to obtain and integrate information from multiple sources; limited parental acceptance of the diagnosis; higher rates of loss to follow-up; and insufficient clinician training.28 Functional neurological symptoms may occasionally manifest in clustered or outbreak patterns, previously termed mass hysteria or mass psychogenic illness, predominantly within pediatric and adolescent populations.293031 Key precipitants include psychosocial stressors, heightened perceived threat, and social transmission mechanisms, whether through direct peer contact or media exposure. Cluster presentations have also been documented in adults.32 While these presentations share phenomenological features with individual FND, the therapeutic approach differs in emphasis. Management prioritizes early diagnostic clarity, transparent communication, limited investigation, and avoidance of excessive medicalization. Coordination with families, educational institutions, and community agencies, is essential to ensure consistent communication and a timely return to normal routines. Mass social media-induced illness presenting with functional tic-like behaviors has been found to carry a generally favorable prognosis, particularly among patients who are male, younger, diagnosed early, have fewer psychiatric comorbidities, and lack ongoing secondary gain or comorbid depression.33 FMD has been documented in elderly populations, with retrospective chart reviews and registry data reporting prevalence rates between 8.2% and 15.3%.3435 The most common presentations are tremor and gait disorders. Diagnostic assessment in this population is complicated by overlapping neurological comorbidities with similar clinical features. For example, functional parkinsonism may be mistaken for idiopathic Parkinson’s disease. Functional weakness can mimic stroke, which the elderly are at increased risk for.35 While clinicians may feel reassured when symptoms are identified as functional, FMDs themselves can be a primary source of disability and should not be dismissed. FND can also present in acute settings, such as the ED.1 Patients may present repeatedly and be mistaken for neurological emergencies such as stroke or transient ischemic attack, particularly in cases of functional weakness or sensory symptoms. Patients may even receive unnecessary treatments such as intravenous (IV) tissue plasminogen activator (tPA).3637 Physicians in the ED therefore play a critical role as part of the interdisciplinary team in recognizing FND and avoiding potentially harmful interventions such as IV tPA. TREATMENT OF FND Physical therapy and rehabilitation FMD is the most extensively studied FND subtype in relation to physical therapy and rehabilitation outcomes. Across multiple studies, both short- and long-term symptomatic improvements have been demonstrated, whether physical therapy is delivered as a stand-alone intervention or combined with other therapeutic modalities in outpatient or inpatient settings.3839 While earlier studies primarily focused on short-term outcomes, with follow-up periods ranging from 8 to 17 months, more recent investigations have assessed longer-term outcomes extending up to 6 years.38394041 Treatment duration varies widely, ranging from as brief as 5 days to as long as 6 months. These interventions are thought to facilitate the use of preserved automatic movement patterns, enabling patients to bypass maladaptive self-focused voluntary motor control rather than directly correcting a structural deficit. Although rehabilitation should be individualized according to each patient’s symptom profile and clinical characteristics, evidence supports the effectiveness of both specialized physiotherapy programs and standard rehabilitation services. In a multicenter, phase 3 RCT, specialized physiotherapy resulted in significant improvements in five secondary outcomes compared with control, including Clinical Global Impression of Improvement (CGI-I) scores, mental health-related quality of life (SF-36), diagnostic confidence, and illness perceptions.42 In addition, a sensory-based occupational therapy intervention involving patients with various FND subtypes (motor, seizure, and speech) produced clinical improvement in 62% of participants, with greater improvement associated with a higher number of treatment sessions.43 Collectively, these findings support rehabilitation as a core component of FMD management. Consistent with this evidence, an international consensus recommendation advocates a biopsychosocial approach to physiotherapy that incorporates patient education, movement retraining, and self-management strategies to address maladaptive illness beliefs, excessive self-focused attention, and abnormal habitual movement patterns.41 Rehabilitation strategies have also been evaluated in other FND subtypes. Vestibular rehabilitation therapy (VRT) has been found to improve symptoms in patients with PPPD, and customized VRT has been shown to have superior therapeutic efficacy compared with virtual reality-based VRT.44 Most RCTs in PPPD have examined single interventions in isolation including customized rehabilitation therapy, cognitive behavioral therapy (CBT), patient education, optokinetic stimulation, vagus nerve stimulation, transcranial direct current stimulation (tDCS) and visual desensitization using personalized glasses.4546 The evidence from these trials supports VRT as an effective component of care, likely by reducing maladaptive attentional focus on postural and visual cues rather than correcting a primary vestibular deficit, although the optimal combination of interventions remains to be established. Future trials examining VRT within multimodal treatment programs are warranted. CBT and other psychological approaches Within the spectrum of FND, CBT has been most extensively studied for functional seizures. Studies have found that CBT is more effective than standard medical care alone in reducing seizure frequency in patients with functional seizures.474849 A multicenter RCT (CODES trial) comparing CBT plus standardized medical care with standardized medical care alone found no statistically significant between-group difference in monthly seizure frequency; however, the CBT group showed clinically meaningful improvements across several secondary outcomes including psychosocial functioning, somatic symptoms, self-reported improvement, and treatment satisfaction.50 Furthermore, a pilot RCT of a novel CBT intervention for pediatric psychogenic nonepileptic seizure (PNES) called Retraining and Control Therapy (ReACT) found that ReACT resulted in significantly greater PNES reduction than supportive therapy, with 100% of patients experiencing no PNES in one week, and 83% remaining PNES-free for 60 days.51 Whether seizure frequency is the most appropriate primary endpoint for trials of psychological interventions in functional seizures remains debated, as improvements in psychosocial functioning, seizure-related distress, and patient-rated global improvement, as observed in the CODES trial, occurred despite no statistically significant reduction in event frequency. Similarly, although the ReACT findings are encouraging, its small sample size and short follow-up period warrant confirmation in larger studies with longer-term follow-up. Emerging evidence also supports the use of CBT in FMD. A pilot single-blind randomized trial demonstrated that CBT combined with rehabilitation was associated with reduced Psychogenic Movement Disorders Rating Scale (PMDRS) scores over 12 weeks.52 Online self-guided CBT, by contrast, has not demonstrated significant benefit in either motor FND or self-rated health outcomes at 3 or 6 months.5354 A recent randomized clinical trial combining physiotherapy with CBT demonstrated improvements in motor symptoms and physical quality of life compared to nondirected psychological support and education.55 Across FND subtypes, CBT is generally directed toward maladaptive symptom-related thoughts, attentional focus, emotional responses, and illness beliefs that may contribute to symptom persistence, rather than toward a single unifying cause. For PPPD, CBT shows meaningful but modest benefits, particularly when combined with other treatments.45 When CBT was delivered alongside vestibular rehabilitation in the INVEST trial, the combined approach produced small to moderate improvements in dizziness handicap, severity, and quality of life compared to standard vestibular rehabilitation alone.56 Combining CBT with sertraline has also yielded larger effects on dizziness handicap than sertraline alone, with statistically significant improvements in dizziness, anxiety, and depression observed only in the combined group.57 CBT alone has been shown to be superior to patient education plus vestibular exercises, though with small between-group effect sizes.58 In summary, while individual interventions including CBT show benefit in PPPD, multimodal treatment combining vestibular rehabilitation, visual desensitization, CBT, and pharmacotherapy warrants further investigation in larger trials with longer follow-up. The evidence base informing treatment of FCD remains limited relative to other FND subtypes.59 An individualized approach is most appropriate, and patients may benefit from neuropsychological therapies including CBT, compassion-focused therapy, or acceptance and commitment therapy. Metacognitive dysfunction has been identified as a potential treatment target in FCD. Because cognitive performance may worsen when it becomes the focus of attention, redirecting attention away from moment-to-moment performance and reducing excessive self-monitoring may plausibly interrupt processes that amplify perceived cognitive failure. This pattern provides a mechanistic rationale for attentional reallocation and metacognitive interventions but should not be interpreted as evidence of established therapeutic efficacy. Interventions including cognitive training, psychoeducation, and lifestyle modification have produced equivocal results. A Delphi consensus study by Cabreira et al.22 proposed that optimal FCD management should include diagnostic communication using the term “functional cognitive disorder,” psychoeducation about internal inconsistency, and individualized psychological intervention, with CBT and acceptance-based approaches cited most frequently. The authors also recommended longitudinal monitoring of cognitive trajectory given the uncertain relationship between FCD and neurodegenerative disease. When FCD co-occurs with subjective cognitive decline or amnestic mild cognitive impairment, the consensus group suggested documenting baseline neuropsychological performance with performance validity measures, repeating assessment at 12–18 months, and screening for mood disorders as confounds. Key differentiating features of FCD from amnestic mild cognitive impairment, subjective cognitive decline, and depression-related cognitive complaints are summarized in Table 4.205960 Multidisciplinary approach The evidence base for multidisciplinary treatment is most developed for functional seizures and FMD. For functional seizures, a systematic review and meta-analysis of three RCTs comprising 450 participants found that CBT added to standardized medical treatment was significantly associated with seizure freedom, as well as reductions in anxiety and improvements in quality of life.61 An earlier RCT demonstrated CBT superiority over standard medical care, with the CBT group reducing median monthly seizures from 12 to 1.5 at six-month follow-up.47 For FMD, RCTs of combined physiotherapy and CBT have shown improvements in motor symptoms and physical quality of life, with 42%–47% of patients reporting improved health at three and five months compared with 26% and 16% in control groups.55 Systematic review evidence further confirms that physiotherapy—whether alone or as part of a multidisciplinary approach—improves motor symptoms, activity, perceived health, and quality of life.62 Together, these findings support the view that combined physical and psychological therapies address both the motor and cognitive-emotional dimensions of FND more comprehensively than either intervention alone. A broader overview of FMD treatment approaches, including physiotherapy and CBT studies, is provided elsewhere.12 For PPPD, a multidisciplinary approach is widely advocated given its complex pathophysiology—encompassing maladaptive postural control, heightened anxiety, and visual dependence—but the direct evidence base for integrated treatment programs remains limited. Most existing trials have tested single interventions in isolation,45 and the effectiveness of combined therapies remains uncertain despite observational improvements.63 The available evidence rests largely on expert consensus and extrapolation from single-intervention studies, and treatment responses vary considerably across individuals. Large-scale randomized trials of multimodal PPPD treatment are needed to establish evidence-based protocols. Hypnosis and psychodynamic psychotherapy Hypnosis and suggestion have been tried for various types of FND and have been found to produce high response rates, with some studies reporting complete or near-complete symptom resolution in up to 76%–81% of patients.64 However, most available studies are limited by methodological weaknesses, and the overall efficacy and optimal treatment parameters of these approaches remain unclear. Although hypnosis may exert its effects through modulation of attention, expectation, and symptom-related beliefs, the high response rates reported in hypnosis studies should be interpreted cautiously given the methodological limitations of most studies and the absence of adequately powered comparative trials with other treatment modalities. Other psychotherapeutic approaches have likewise been examined in FMD. A retrospective, open-label observational study of psychodynamic psychotherapy in patients with FMD found significant post-treatment improvements in motor symptom severity, functional disability, and quality of life—with benefits extending beyond changes in psychiatric symptoms alone.65 Treatment response was greater among patients who engaged consistently and were able to identify psychological factors contributing to their symptoms. These findings suggest that individualized, emotion-focused psychotherapy may be beneficial for selected patients within a multidisciplinary framework. Neuromodulation Non-invasive neurostimulation techniques, including transcranial magnetic stimulation (TMS), tDCS, and peripheral nerve stimulation, are increasingly being explored as treatments for FMD. However, study protocols are heterogeneous and evidence for efficacy remains preliminary.66 Most studies have used TMS or repetitive TMS (rTMS), with a limited number investigating tDCS. These studies have examined a range of FND phenotypes, including FMD with positive and negative motor symptoms, functional seizures, and less common presentations such as aphonia and functional visual loss.67 Among the RCTs conducted, three warrant particular attention. Taib et al.68 randomized 18 patients with functional tremor to active low-frequency rTMS (1 Hz, 800 pulses over 5 sessions) or sham over the motor cortex. PMDRS scores decreased in both groups at one month but reached statistical significance only in the active group (p<0.001), with effects maintained at 6 and 12 months; control group scores returned to near-baseline by month 2. Broersma et al.,69 in a crossover RCT of 11 patients with functional paresis, found that high-frequency rTMS (5 Hz, 9,000 pulses over 10 sessions) targeting the contralateral motor cortex produced a significant objective increase in muscle strength by dynamometry compared to real electromagnetic placebo, though no significant difference was observed in subjective symptom ratings. In contrast, Garcin et al.70 (n=33, FMD) reported clinical improvement in both the active and control groups, with no significant between-group differences, suggesting that the effects of TMS in FMD may be mediated more by cognitive–behavioral mechanisms than by direct cortical neuromodulation. These three randomized trials yielded heterogeneous findings, likely reflecting differences in patient populations, stimulation protocols, outcome measures, and control conditions. Although some studies reported greater improvements with active stimulation than with control conditions, the absence of between-group differences in the trial by Garcin et al.70 suggests that at least some of the observed benefits may be mediated by nonspecific mechanisms, including expectation and attention, rather than direct cortical neuromodulation alone. Evidence for both TMS and tDCS in FND remains limited by significant heterogeneity in study design, stimulation parameters, FND phenotype, and outcome measures, preventing definitive conclusions about efficacy. A further limitation is the predominant focus on the motor cortex as a stimulation target, despite limited evidence of motor cortex abnormalities in FND.71 Emerging evidence supports neurobiologically informed targets, including the right temporoparietal junction (rTPJ), implicated in aberrant sense of agency, and the dorsolateral prefrontal cortex (DLPFC), selected via individualized resting-state functional neuroimaging.7273 Pharmacological treatment Pharmacological treatment for FND has been most studied in FDS. A four-arm placebo-controlled RCT by LaFrance et al.74 compared sertraline alone, CBT alone, combined CBT plus sertraline, and treatment-as-usual in adults with functional seizures over 16 weeks. While no active treatment arm met the pre-specified threshold for statistical superiority on the primary outcome of seizure reduction, both CBT alone and combined CBT plus sertraline produced significant improvements in psychosocial outcomes including depression, anxiety, quality of life, and global functioning. Sertraline alone improved psychosocial functioning but not seizure frequency. Accordingly, the 2026 AAN guideline recommends against prescribing benzodiazepines or antiseizure medications for functional seizures in the absence of a separate indication and advises tapering of unnecessary medications where clinically feasible.75 For other FND subtypes, pharmacological evidence is more limited. For PPPD, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are the pharmacological agents most supported by clinical evidence; sertraline combined with CBT has demonstrated superior outcomes to sertraline alone on dizziness, anxiety, and depression.57 For FMD and FCD, there is no established pharmacological treatment targeting core symptoms directly; treatment of comorbid depression, anxiety, or pain with standard agents remains important and may improve outcomes in rehabilitation and psychotherapy. Other types of treatment OnabotulinumtoxinA has been investigated in combination with CBT for functional dystonia.76 In a pilot randomized trial, patients with functional dystonia (PMDRS score ≥10 and persistent dystonic posturing for ≥1 year) received onabotulinumtoxinA or placebo prior to 12 weekly CBT sessions. While no significant between-group differences in clinical assessments were found at 12 weeks, both groups demonstrated a meaningful improvement in dystonia severity following CBT. Botulinum neurotoxin has also been evaluated in jerky and tremulous FMD, with a double-blind RCT finding no evidence of improved outcomes—including symptom severity, disease burden, quality of life, disability, or psychiatric symptoms—compared with placebo.77 Physical activity and exercise have not been studied in detail specifically in FND; however, there is preliminary evidence of therapeutic benefit in conditions that commonly co-occur with FND, such as fibromyalgia, persistent post-concussion symptoms, postural orthostatic tachycardia syndrome, chronic pain, and chronic fatigue syndrome. Whether structured exercise provides benefits beyond those achieved through established rehabilitation approaches in FND remains unclear. GUIDELINES ON MANAGEMENT OF FUNCTIONAL SEIZURES Recently, the AAN released practice guidelines on the management of functional seizures, outlining evidence-based recommendations for clinicians, patients, and the broader care network. Consistent with the 2025 ILAE proposal, the term “functional/dissociative seizures” (FDS) is now preferred over “psychogenic nonepileptic seizures” (PNES).75 The guidelines identify accurate diagnosis as foundational, recommending detailed clinical history, careful assessment of semiology (including patient- or witness-recorded videos), and video-electroencephalography (EEG) when feasible, alongside evaluation for comorbid psychiatric conditions and epilepsy. Psychological interventions are supported as associated with modest but clinically meaningful improvements—including increased rates of seizure freedom, reduced seizure frequency, and better anxiety and quality of life outcomes. The guidelines also emphasize patient-centered care throughout, calling for clear and non-stigmatizing communication of the diagnosis, shared decision-making, involvement of family or support systems, and continuity of care. With respect to pharmacological management, the guidelines recommend against the use of benzodiazepines or antiseizure medications in the absence of other indications and advise tapering of unnecessary medications where appropriate. To date, similarly comprehensive evidence-based clinical practice guidelines are not available for most other FND subtypes, although consensus recommendations have been published for physiotherapy in functional motor disorders and for other rehabilitation disciplines.41 Although the guideline endorses psychological interventions broadly, much of the available evidence reviewed was derived from studies of CBT-based and other condition-specific psychotherapies. Because multiple studies were available, CBT was the only modality analyzed separately. Other psychotherapeutic approaches discussed in this review, including psychodynamic therapy and hypnosis, were not evaluated separately. Coexisting FDS and epileptic seizures represent an important clinical challenge. Because the two seizure types require different treatments, accurate characterization of each event type is essential, with video-EEG monitoring considered the diagnostic gold standard when a typical event can be captured and the test is feasible. The AAN guideline recommends continuing antiseizure medications when indicated for coexisting epilepsy while avoiding unnecessary treatment for functional seizures alone. Psychological interventions for functional seizures may be pursued alongside appropriate antiseizure treatment for epilepsy. Clear, empathetic, and non-stigmatizing communication regarding the coexistence of two distinct diagnoses and their respective treatment approaches is essential for promoting treatment engagement and adherence. OUTCOME MEASURES OF FNDs FND is a common and disabling condition, yet research into appropriate outcome measures has been scarce. Quantification of symptom severity in FND presents several challenges.78 First, FND presents across a wide range of symptom types that mimic the full spectrum of other neurological disorders, making it difficult to identify a single measurement approach that works across subtypes. Second, FND commonly co-occurs with additional physical symptoms (such as pain and fatigue) and psychological symptoms (such as depression and anxiety), all of which warrant assessment but have an unclear etiological relationship to FND itself. Third, the standard practice of prioritizing “objective” clinician-rated measures over “subjective” patient-reported measures may be inappropriate for FND, given the nature of the condition; self-report measures may be more clinically meaningful in this population. A systematic review identified five FND-specific outcome measures79: three clinician-rated scales—a rating scale for functional seizures, the PMDRS, and the Simplified Functional Movement Disorder Rating Scale—and two patient-rated measures, the Conversion Disorder Scale (CDS) and the CDS-Revised. The limited number of validated, FND-specific tools underscores the need for further development and standardization of outcome measures across subtypes. STIGMA, EMOTIONAL PROCESSING AND THE PATIENT EXPERIENCE A recent systematic review of 127 studies across 148 countries, involving nearly 19,000 participants, found that stigma in FND has been most extensively studied in patients with functional seizures.10 Stigma was higher in patients with functional seizures than in those with epilepsy and was associated with poorer quality of life and greater caregiver burden.8081 Patients with functional neurological or other somatic symptoms commonly describe an experience marked by distress, uncertainty, and difficulty in making sense of what is happening to them. Symptoms are frequently multiple, variable, and highly disruptive to daily functioning, and are often accompanied by intense negative emotions including fear, powerlessness, anger, and shame.82 Many patients report a pervasive sense that their symptoms are beyond their control, and some conceal them from others out of fear of being disbelieved or stigmatized. In acute settings, patients with functional symptoms have described feeling confused about their diagnosis, concerned that clinicians perceived them as wasting time, and dissatisfied with the explanations they received.83 This sense of not being taken seriously—or of being implicitly blamed for one’s own symptoms—is a recurring theme across both primary and acute care contexts. While some patients found that accepting a psychological explanation for their symptoms was empowering and facilitated better coping, others experienced this framing as delegitimizing, reinforcing a sense that their suffering was not genuine. Patient memoirs describing lived experience with FND consistently highlight diagnostic uncertainty, stigma, and fluctuating symptoms as central challenges, while identifying validation, clear communication, and multidisciplinary care as factors that shape recovery. Altered emotional processing is increasingly recognized as a key pathophysiological feature of FND, potentially serving as a mechanistic link between psychosocial risk factors and the generation of neurological symptoms.84 Patients frequently report difficulties in emotional functioning, including anxiety, depression, alexithymia, and affect dysregulation, and greater affective dysfunction is associated with poorer quality of life, increased symptom severity, and elevated dissociation. Behaviorally, one of the most consistent experimental findings is an implicit attentional bias toward emotionally salient stimuli, particularly facial expressions of anger and happiness, in patients with functional seizures.8586 Neuroimaging studies consistently show elevated amygdala reactivity during emotional processing in FND, linked to adverse life events, hypothalamic–pituitary–adrenal axis (HPA axis) dysfunction, and symptom severity. A key finding is abnormally enhanced connectivity between the amygdala and motor regions, particularly the supplementary motor area, which is thought to facilitate automatic motor responses in emotionally arousing contexts and may help explain how emotional states contribute to FND symptom generation.878889 At the level of autonomic and interoceptive function, patients with FND demonstrate elevated baseline arousal, including raised cortisol, heart rate, and skin conductance alongside reduced heart rate variability, suggesting chronic physiological dysregulation.9091 Evidence also points to impaired top-down emotion regulation reflected in altered prefrontal engagement—including the DLPFC and anterior cingulate cortex—during affective tasks.84 Furthermore, patients show a discrepancy between subjective and psychophysiological responses during emotional processing, suggesting impaired interoceptive awareness.92 This interoceptive dysfunction has been proposed to be shaped by early adverse caregiving environments, causing internal bodily signals to be weighted less than external inputs and emotional distress to be misinterpreted as somatic or neurological symptoms.93 Taken together, these findings support a model in which FND symptoms may represent forms of learned affective responses that are shaped by prior experience, amplified by chronic autonomic dysregulation, and expressed through aberrant limbic-motor interactions. PROGNOSIS OF FND Studies examining the prognosis of FND are scarce, but those available tend to indicate a poor overall outcome.5 Despite these findings, multiple studies have shown that improvements achieved through rehabilitation can be maintained over time.94 A 4-week inpatient intensive rehabilitation study for motor FND found improved functional motor outcomes at long-term follow-up (average of 36 months).95 Negative prognostic factors include older age, comorbid psychiatric disorders such as anxiety or depression, lower educational attainment, poor general health, chronic pain, and pending litigation. Prognosis varies across FND subtypes. For functional seizures, short-term seizure control has been relatively encouraging, and a recent long-term study found that approximately 46% of patients reported being seizure-free following diagnosis in an epilepsy monitoring unit.96 Functional limb weakness, by contrast, tends to be persistent and disabling and has been associated with higher long-term mortality; general health at baseline and pain are among the factors most consistently associated with outcome.97 Fixed dystonia, which frequently overlaps with complex regional pain syndrome, carries a particularly unfavorable prognosis, with improvement reported in fewer than 25% of patients, major remission in approximately 6%, and worsening in 33%.98 A study examining predictors of response to an intensive outpatient FMD program found that patients who completed a therapeutic screening prior to the program and reported improvement during that screening period had better patient-reported outcomes at the end of treatment.99 Prognosis and factors associated with outcome in FMD have been reviewed in greater detail elsewhere.12 CONCLUSION FND is a prevalent and disabling condition whose clinical and scientific understanding has advanced considerably over the past decade. A key conceptual shift—from diagnosis by exclusion to rule-in diagnosis based on positive clinical signs—has improved diagnostic accuracy and aligned clinical practice with a more mechanistically grounded framework.61314 FND involves dysfunction across multiple brain networks, including aberrant predictive coding, disrupted sense of agency mediated through the rTPJ, limbic hyperactivation, and impaired interoception—mechanisms shared, to varying degrees, across its subtypes, including functional seizures, FMD, PPPD, and FCD.5 This shared pathophysiological substrate has direct implications for treatment. Physical therapy for FMD utilizes preserved automaticity of movement to bypass aberrant voluntary motor control383941; vestibular rehabilitation in PPPD targets an overlearned attentional focus on dizziness44; and CBT across subtypes addresses interoceptive biases, emotion dysregulation, and maladaptive illness beliefs that contribute to symptom perpetuation.47505657 Multidisciplinary treatment combining physiotherapy, psychological intervention, and management of comorbidities carries the strongest evidence and represents the current standard of care, though it remains inaccessible to many patients worldwide.6556162 Despite this progress, long-term outcomes remain poor in a substantial proportion of patients, with approximately 40% unchanged or worse over time and sustained remission achieved in a minority.100 Healthcare costs for inpatient FND care in the United States alone exceed one billion dollars annually.3 Research on FCD and PPPD is more limited than for functional seizures and FMD, with few clinical practice guidelines, and no validated biomarkers currently available for routine diagnosis or treatment monitoring at the individual level.757879 For clinicians in South Korea, where dedicated multidisciplinary FND programs are not widely available, practical approaches to diagnosis and management are particularly important. A positive diagnosis can be communicated effectively even in a busy outpatient setting through demonstration of positive neurological signs, clear explanation of the diagnosis, and provision of reliable educational resources such as http://www.neurosymptoms.org. In the absence of specialized physiotherapy or formal CBT programs, collaboration with physical therapists familiar with FND principles and the use of psychoeducational and self-guided CBT materials may represent reasonable alternatives. Within the Korean National Health Insurance system, access to evidence-based psychological treatment for FND remains limited. Reimbursement for structured psychotherapy is restricted, and many psychological services provided in community or private practice settings are not covered, creating substantial financial barriers for patients. Disability certification also presents challenges because FND is not recognized as an independent disability category under South Korea’s disability registration system. Although some patients with severe functional impairment may be evaluated under existing neurological or psychiatric disability categories, eligibility is often difficult in the absence of structural neurological lesions and because certification criteria are based on established disability definitions. Clinicians should counsel patients regarding these practical limitations, particularly when discussing long-term treatment planning and access to social welfare or vocational support. Expanding clinician education and reducing stigma remain essential steps toward improving access to care and establishing scalable multidisciplinary treatment pathways. Future research priorities include: 1) establishing evidence-based clinical practice guidelines across all FND subtypes, analogous to the 2026 AAN functional seizures guideline; 2) conducting adequately powered, multimodal randomized trials for PPPD and FCD, where evidence is most limited; 3) developing neurobiologically informed neuromodulation targets beyond the motor cortex, with individualized selection guided by resting-state functional neuroimaging; 4) validating biomarkers for diagnosis and treatment monitoring at the individual level; 5) standardizing outcome measures across FND subtypes and clinical settings; and 6) designing implementation research to establish scalable multidisciplinary care models in healthcare systems with limited specialist access. Continued investment in clinician education and stigma reduction remains equally important, as patients with FND often face substantial stigma and varying degrees of disability.10 Notably, patient-authored accounts, including memoirs and other forms of narrative, may serve a complementary role in this effort, offering both a means of personal meaning-making and a resource for broadening public and clinical understanding of the lived experience of FND. The diagnosis of FND should be approached as an opportunity to identify a potentially treatable cause of neurological disability and to initiate interventions that may improve symptoms and functional outcomes.